Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes
Chlup R, Seckar P, Zapletalova J, Langova K, Kudlova P, Chlupova K,
A product (compound) patent is the hardest to design around because the generic must contain the same API as the brand
This is a great guide to help you know more about how GLP-1s act in the body and also to help provide education to your clients
Voutilainen S, Morrow JD, Roberts LJ II, Alfthan G, Alho H, Nyyssnen K, and Salonen JT (1999)